After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Background The growing population of patients with adult congenital heart disease (ACHD) present complex lifelong care needs ...

The King Abdullah University Hospital (KAUH) has performed its first catheter-based cardiac ablation procedures for the treatment of cardiac arrhythmias, using advanced electrophysiology and cardiac ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.

Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for patients with atrial fibrillation (AFib). The approval follows earlier CE ...